Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

not met at the highest dose evaluated as monotherapy (1000 mg). - No evidence of altered cardiac activity was observed. - Majority of adverse events were mild and mainly occurred during the loading doses. Adverse events consisted of chills, itching and fatigue in over a third of patients. - There was a trend for increasing incidence of some mild adverse events with escalating OGX-427 doses. For example, 33% of patients at the 200-mg dose compared to 67% of patients at the 1000-mg dose had mild adverse events during the loading doses. - The half-life of OGX-427 in the blood remained constant, although there appeared to be an increase in maximum blood levels and a corresponding decease in blood clearance of OGX-427 as doses were escalated.

The combination of 800 mg OGX-427 with docetaxel was also well tolerated and escalation to 1000 mg OGX-427 with docetaxel will be evaluated next.

Circulating Tumor Cell and Tumor Marker Results

Circulating tumor cells (CTCs), an emerging metric to assess treatment effect, was evaluated at baseline before treatment and during treatment. Both total and Hsp27-positive CTCs were evaluated. Declines of 50% or greater in both total and Hsp27-positive CTCs were observed in over half of the patients in each cohort and in each cancer category. Declines in Hsp27 CTCs to 5 or less cells occurred in 27% of patients who had greater than 5 CTCs at baseline.

Reduction in tumor markers defined as declines of PSA levels in prostate cancer or CA-125 levels in ovarian cancer were also observed. A reduction in PSA level was observed in 7 of 20 patients (35%) with prostate cancer and a reduction in CA-125 levels was observed in 3 of 5 patients (60%) with ovarian cancer.

"CTCs are emerging as an exciting surrogate of anti-cancer activity. The frequent decreases in total
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Washington, DC (PRWEB) January 14, 2014 ... session for Thursday, January 23, 2014 at 2pm EST ... Actionable Knowledge.” The topic focuses on how technology can ... mission critical decisions for government agencies. The online webinar ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... the universe looked like when it was a baby. They ... is how it looked in its youth. Thanks to technological ... provide a picture of how the cosmos developed into the ... on Earth. They plan to gather these never-before-obtained insights ...
... Dendreon Corporation (Nasdaq: DNDN ) ... for on-label use of PROVENGE® (sipuleucel-T), the first ... or minimally symptomatic metastatic castrate resistant (hormone refractory) ... The U.S. Food and Drug Administration (FDA) approved ...
... 2011 PracticeMatch, based in St. Louis, Mo., announces ... service to connect physicians with potential employers. These events ... training to speak face-to-face with representatives from some of ... program relations specialist for PracticeMatch, says the goal of ...
Cached Biology Technology:Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 2Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 3Scientists hope to get glimpse of adolescent universe from revolutionary instrument-on-a-chip 4Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 2Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 3Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE 4PracticeMatch Now Offers Free Physician Career Fairs 2
(Date:4/17/2014)... in the Cell Press journal Current Biology ... rather novel sex lives. The Brazilian insects, which represent ... Neotrogla , are the first example of an animal ... been identified in several different animals, Neotrogla ... is also reversed," says Kazunori Yoshizawa from Hokkaido University ...
(Date:4/17/2014)... uncovered a new way the immune system may fight ... to use immune cells to treat illness. , The ... immunological equivalent of "neighborhood police" specialized squads of ... instead of an entire city, the body. , Scientists ... have shown that the liver, skin and uterus each ...
(Date:4/16/2014)... forgotten in museum collections two new species of yellow-shouldered bats have ... and The Field Museum of Natural History and described in the ... additions to the genus Sturnira are part of a ... world, the third one still waiting to be officially announced. , ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Some immune cells defend only 1 organ 2Two new species of yellow-shouldered bats endemic to the Neotropics 2
... make cholesterol, a team of scientists has discovered ... production and potentially drug metabolism. , The collaborative ... of Medicine, Vanderbilt University, Indiana University and Eli ... of Cell Metabolism. , “Dap1 controls ...
... A new study concludes that low birthweight babies born with ... large quantities of dietary sodium later in life. In ... severe cases of low sodium blood serum consumed ~1700 mg ... than their peers. These data, taken together with other ...
... have developed an adaptive strategy to help natural resource ... and respond to disturbance from major hurricanes. In an ... John Stanturf, Scott Goodrick, and Ken Outcalt from the ... GA, report the results of a case study based ...
Cached Biology News:Primitive yeast yields secrets of human cholesterol and drug metabolism 2Like salty food? Chances are you had low blood sodium when you were born 2Like salty food? Chances are you had low blood sodium when you were born 3How to manage forests in hurricane impact zones 2How to manage forests in hurricane impact zones 3